Oxford joins consortium to advance quantum drug discovery
The partnership between Oxford University and SEEQC promises to accelerate the use of quantum computing within pharmaceutical research in order to reduce the development time required for drug production worldwide.
Oxford University has joined a consortium led by the digital quantum computing company, SEEQC, to build and deliver a full-stack quantum computer for pharmaceutical drug development for Merck KGaA.
The consortium has been awarded a £6.85m grant, by Innovate UK’s Industrial Strategy Challenge Fund (ISCF) to build a commercially scalable quantum computer designed to tackle prohibitively high costs within pharmaceutical drug development.
Matthew Hutchings, co-founder and chief product officer at SEEQC, shared: “Today, drug discovery is a labour and time-intensive iterative process with immense costs. Thanks to our world-leading partners and the invaluable commercial benchmarking by our end-customers at Merck, we have the opportunity to develop a quantum computing platform that can radically improve the efficiency of drug development.”
The partnership will accelerate the use of quantum computing within pharmaceutical research to dramatically reduce the time required for drug development on a global scale.
Read more: https://www.pharmatimes.com/news/oxford_joins_consortium_to_advance_quantum_drug_discovery_1386106
Oxford University has joined a consortium led by the digital quantum computing company, SEEQC, to build and deliver a full-stack quantum computer for pharmaceutical drug development for Merck KGaA.
The consortium has been awarded a £6.85m grant, by Innovate UK’s Industrial Strategy Challenge Fund (ISCF) to build a commercially scalable quantum computer designed to tackle prohibitively high costs within pharmaceutical drug development.
Matthew Hutchings, co-founder and chief product officer at SEEQC, shared: “Today, drug discovery is a labour and time-intensive iterative process with immense costs. Thanks to our world-leading partners and the invaluable commercial benchmarking by our end-customers at Merck, we have the opportunity to develop a quantum computing platform that can radically improve the efficiency of drug development.”
The partnership will accelerate the use of quantum computing within pharmaceutical research to dramatically reduce the time required for drug development on a global scale.
Read more: https://www.pharmatimes.com/news/oxford_joins_consortium_to_advance_quantum_drug_discovery_1386106
